The BOASBERG Act mandates that federal district and appellate courts use random methods to assign civil cases and judges to panels, ensuring that no party, attorney, or judge can influence which judge hears a specific case. While this randomization applies broadly, the bill allows for exceptions in limited situations such as when a judge must recuse themselves, when cases are consolidated for efficiency, or when a chief judge certifies a need for reassignment based on docket management rather than the parties involved. The legislation also requires courts to publish transparency reports explaining any deviations from random assignment and imposes penalties, including sanctions or disciplinary action, on individuals who attempt to manipulate the assignment system.
S 2658, the Medication Affordability and Patent Integrity Act, requires drug manufacturers to certify that patent information submitted to the FDA for new drug approvals matches what they provided to the U.S. Patent and Trademark Office (USPTO). It mandates that sponsors submit patent-related data to the USPTO and certify its accuracy, ensuring consistency between FDA and patent filings for drugs and biologics. The bill creates a new legal defense for generic drug makers in patent lawsuits if a brand-name company failed to disclose required patent information. This applies to new drug applications filed after the law's enactment, directly affecting pharmaceutical companies seeking FDA approval for new medications.
The Patients Deserve Price Tags Act requires hospitals, clinical diagnostic laboratories, imaging services providers, and ambulatory surgical centers to publicly disclose detailed pricing information for healthcare services in machine-readable formats. This includes standard charges, discounted cash prices, payer-specific negotiated rates, and other relevant pricing data that consumers can easily access and compare. The law applies to all facilities that provide services to Medicare beneficiaries, with implementation dates starting in 2026 for hospitals and 2027 for other providers. Non-compliant facilities face daily civil monetary penalties ranging from $300 to $10,000 per day, depending on facility size and duration of non-compliance.
This bill simplifies the approval process for biosimilar drugs - medicines that are highly similar to, but not identical to, existing biologic drugs. It amends the Public Health Service Act to clarify when biosimilars are deemed "interchangeable" with the original drug (allowing pharmacists to substitute them without a doctor's specific order), adjusts exclusivity periods for existing biosimilars, and sets a 60-day transition period after enactment. The bill also requires the FDA to update its guidance documents within 18 months to reflect these changes. This directly affects pharmaceutical companies developing biosimilars, the FDA in its review process, and ultimately patients seeking more affordable treatment options.
This resolution expresses the sense of the House of Representatives that Charleston, South Carolina, should proceed with hosting the 2027 annual meeting of the Organization for Security and Cooperation in Europe Parliamentary Assembly. The bill cites Charleston's existing facilities as suitable for the event and notes that hosting the convention in South Carolina honors the legacy of late Senator Lindsey Olin Graham. It also highlights that the United States has not hosted this specific assembly since 2005. The measure does not change any laws or allocate funding but serves as a formal statement of support for the planned event.
The Temporary Protected Status Review Act restores the ability of courts to review decisions by the Department of Homeland Security to end Temporary Protected Status (TPS) designations for foreign nationals. Under this bill, the government must publish detailed written findings explaining why a country no longer qualifies for TPS protection, and these decisions would be subject to a legal challenge in federal court. If a TPS designation is terminated, the affected individuals would remain in the United States with their current status and work authorization intact while the legal challenge is pending. Additionally, the legislation requires the government to follow specific administrative procedures, such as considering all available evidence and avoiding bias, before making any termination decisions.
This bill establishes federal protections and funding to expand access to in vitro fertilization and intrauterine insemination for individuals, military service members, and veterans. It requires most private health plans, Medicaid programs, and Medicare to cover these fertility treatments without imposing higher cost-sharing than other medical services. Additionally, the legislation mandates that the Department of Defense and the Department of Veterans Affairs provide specific fertility preservation and treatment benefits to uniformed service members and eligible veterans. The bill also includes preemption clauses that override state laws restricting these procedures and prohibits discrimination based on marital status, sex, or sexual orientation in the provision of care.
The Transportation for Reentry Act requires transit agencies receiving federal funding to offer free public transportation to individuals released from prison after serving at least one year. Under this bill, these agencies must provide the service for one year starting from the person's release date and cover costs related to program setup, staff training, and outreach. To receive federal grants, transit recipients must establish enrollment systems, track usage data, and ensure compliance with the program's duration requirements. The legislation authorizes $40 million annually from 2027 to 2031 to support these efforts and mandates a final report on the program's impact five years after enactment.
This bill reauthorizes and expands the Accelerating Access to Critical Therapies for ALS Act through 2031, extending funding for research into treatments for amyotrophic lateral sclerosis. It requires drug manufacturers to share interim clinical trial data with the FDA to better assess the progress of investigational drugs and clarifies that phase 3 clinical trial definitions include combined phase 2/3 trials and planned trials not yet enrolling participants. The legislation also mandates the FDA to publish an updated five-year action plan for ALS and other rare neurodegenerative diseases, including resource needs and coordination strategies with broader disease communities. Additionally, the bill requires the Government Accountability Office to submit a report on the program's implementation four years after enactment.
This bill extends the deadline for the National Emergency Medical Services Memorial Foundation to establish a commemorative memorial in Washington D.C. and its surrounding areas to November 3, 2032. It directly affects the foundation by modifying the expiration date previously set to end a 7-year period. The change ensures the foundation has sufficient time to complete its memorial work within the updated timeframe.
The Inclusive Democracy Act of 2026 mandates that individuals with criminal convictions retain their right to vote in federal elections and requires prisons, jails, and probation offices to notify incarcerated or supervised individuals of this right. The bill establishes specific procedures for voter registration and absentee voting within carceral settings, including expedited transmission of forms and the ability to use either a prison address or a last known address for registration. It also prohibits states from rejecting ballots or registration applications based on late mailing dates or electronic submission methods and ensures that election materials and nonpartisan voter registration services can be distributed inside correctional facilities.
The Preventing Forced Abortions Act of 2026 prohibits federal courts from enforcing any part of a surrogacy agreement that forces a surrogate mother to have an abortion. Instead, the law mandates that courts must uphold the financial compensation promised to the surrogate, even if the contract includes penalties or reduced payments for refusing an abortion. This legislation grants federal district courts specific authority to hear civil cases involving surrogacy contracts and defines key terms such as "abortion" and "surrogate mother" to clarify the scope of the protections.
